Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
185 hedge funds and large institutions have $759M invested in Day One Biopharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 74 increasing their positions, 43 reducing their positions, and 33 closing their positions.
72% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 43
33% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 33
10% more call options, than puts
Call options by funds: $7.37M | Put options by funds: $6.69M
6% more funds holding
Funds holding: 174 → 185 (+11)
4.39% less ownership
Funds ownership: 83.73% → 79.35% (-4.4%)
14% less capital inflows, than outflows
Capital inflows: $145M | Capital outflows: $168M
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vestal Point Capital
New York
|
+$21.1M |
| 2 |
Jefferies Financial Group
New York
|
+$9.37M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.76M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$6.09M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$36.6M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$28.6M |
| 3 |
Rubric Capital Management (New York)
New York
|
-$23.8M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$15.6M |
| 5 |
Braidwell
Stamford,
Connecticut
|
-$15.4M |
DAWN Hedge Fund Activity: Q4 2025 in Review
185 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q4 2025, worth a combined $759M — up 26% from $605M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new DAWN positions and 33 closed out — a net gain of 11 holders — while 74 added to existing stakes and 43 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $21.1M. The largest seller was Fidelity Investments, cutting an estimated $36.6M.
- 185 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q4 2025, up from 174 in Q3 2025.
- Funds reported $759M of Day One Biopharmaceuticals stock for Q4 2025, up 26% quarter-over-quarter.
- 44 funds opened new Day One Biopharmaceuticals positions in Q4 2025 and 33 closed out, a net change of +11 holders.
- The largest Day One Biopharmaceuticals buyer in Q4 2025 was Vestal Point Capital, an estimated $21.1M added.
- The largest Day One Biopharmaceuticals seller in Q4 2025 was Fidelity Investments, an estimated $36.6M sold.
Based on aggregated 13F filings for Q4 2025.